Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder

• Status: Recruiting
• Trial end date: 2022-08-15
• Target enrollment: 0
• Participant gender: All

Summary

Overactive bladder is more prevalent among the Sjogren syndrome's population compare to the general population. Both anti-muscarinic agent and beta-3 agonist are recommended as second line treatment for overactive bladder syndrome. However, theoretically, undesirable effect of the anti-muscarinic agent such as dry mouth and constipation would make it less suitable for Sjogren syndrome patient with overactive bladder. Therefore, this study is a randomised control study with the aim to evaluate the therapeutic effect of beta-3 agonist and anti-muscarinic agent on overactive bladder among sjogren's syndrome patient.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: China Medical University Hospital
• Treatments: Mirabegron; Oxybutynin; Solifenacin Succinate; Tolterodine Tartrate

Criteria

Inclusion Criteria:

• Diagnosis of Sjogren's syndrome AND

• Clinical diagnosis of OAB

Exclusion Criteria:

• Congenital or acquired anatomic abnormalities of the genitourinary tract,

• Uncontrolled severe hypertension >180 mmHg

• Cannot cooperate for voiding diary documentation